Financial Toxicity in Patients With Resected Lung Cancer.
Journal
Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354
Informations de publication
Date de publication:
01 12 2023
01 12 2023
Historique:
medline:
9
11
2023
pubmed:
30
5
2023
entrez:
30
5
2023
Statut:
ppublish
Résumé
To describe financial toxicity (FT) in patients with resected lung cancer and identify risk factors in this population. FT describes the financial burden associated with cancer care and its impact on the quality of survivorship. Few prior studies have examined FT in patients with lung cancer. Patients who underwent lung cancer resection at our institution between January 1, 2016 and December 31, 2021, were surveyed to gather demographic information and evaluate FT using a validated questionnaire. A multivariable model was built to identify risk factors for FT. Of the total, 1477 patients were contacted, of whom 463 responded (31.3%). Most patients were stage I (n = 349, 75.4%) and lobectomy was performed often (n = 290, 62.8%). There were 196 patients (42.3%) who experienced FT. Upon multivariable analyses, divorced marital status [odds ratio (OR) = 3.658, 95% CI: 1.180-11.337], household income <$40,000 (OR = 2.544, 95% CI: 1.003-6.455), credit score below 739 (OR = 2.744, 95% CI: 1.326-5.679), clinical stage >I (OR = 2.053, 95% CI: 1.088-3.877), and change in work hours or work cessation (all P < 0.05) were associated with FT. Coping mechanisms, such as decreased spending on food or clothing and increased use of savings or borrowing money, were more likely to be reported by patients experiencing FT than those who did not ( P < 0.001). Patients undergoing lung cancer resection often experienced significant financial stress with several identifiable risk factors. FT should be considered early in the care of these patients to alleviate detrimental coping mechanisms and enhance their quality of survivorship.
Sections du résumé
OBJECTIVES
To describe financial toxicity (FT) in patients with resected lung cancer and identify risk factors in this population.
BACKGROUND
FT describes the financial burden associated with cancer care and its impact on the quality of survivorship. Few prior studies have examined FT in patients with lung cancer.
METHODS
Patients who underwent lung cancer resection at our institution between January 1, 2016 and December 31, 2021, were surveyed to gather demographic information and evaluate FT using a validated questionnaire. A multivariable model was built to identify risk factors for FT.
RESULTS
Of the total, 1477 patients were contacted, of whom 463 responded (31.3%). Most patients were stage I (n = 349, 75.4%) and lobectomy was performed often (n = 290, 62.8%). There were 196 patients (42.3%) who experienced FT. Upon multivariable analyses, divorced marital status [odds ratio (OR) = 3.658, 95% CI: 1.180-11.337], household income <$40,000 (OR = 2.544, 95% CI: 1.003-6.455), credit score below 739 (OR = 2.744, 95% CI: 1.326-5.679), clinical stage >I (OR = 2.053, 95% CI: 1.088-3.877), and change in work hours or work cessation (all P < 0.05) were associated with FT. Coping mechanisms, such as decreased spending on food or clothing and increased use of savings or borrowing money, were more likely to be reported by patients experiencing FT than those who did not ( P < 0.001).
CONCLUSIONS
Patients undergoing lung cancer resection often experienced significant financial stress with several identifiable risk factors. FT should be considered early in the care of these patients to alleviate detrimental coping mechanisms and enhance their quality of survivorship.
Identifiants
pubmed: 37249193
doi: 10.1097/SLA.0000000000005926
pii: 00000658-202312000-00029
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1038-1044Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Deboever N, Mitchell KG, Feldman HA, et al. Current surgical indications for non-small-cell lung cancer. Cancers. 2022;14:1263.
Shu CA, Cascone T. What is neo? Chemoimmunotherapy in the neoadjuvant setting for resectable non–small-cell lung cancer. J Clin Oncol. 2021;39:2855–2858.
Witte J, Mehlis K, Surmann B, et al. Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications. Ann Oncol. 2019;30:1061–1070.
Schröder SL, Schumann N, Fink A, et al. Coping mechanisms for financial toxicity: a qualitative study of cancer patients’ experiences in Germany. Support Care Cancer. 2020;28:1131–1139.
Patel MR, Zhang G, Heisler M, et al. Measurement and validation of the comprehensive score for financial toxicity (COST) in a population with diabetes. Diabetes Care. 2022;45:2535–2543.
Asaad M, Boukovalas S, Chu CK, et al. Financial toxicity and contralateral prophylactic mastectomy: an analysis using propensity score methods. Breast Cancer Res Treat. 2020;183:649–659.
Bailey CM, Asaad M, Boukovalas S, et al. Understanding the relationship between breast reconstruction subtype and risk of financial toxicity: a single-institution pilot study. Plast Reconstr Surg. 2021;148:1e–11e.
Coroneos CJ, Lin Y-L, Sidey-Gibbons C, et al. Correlation between financial toxicity, quality of life, and patient satisfaction in an insured population of breast cancer surgical patients: a single-institution retrospective study. J Am Coll Surg. 2021;232:253–263.
Offodile nAC, Asaad M, Boukovalas S, et al. Financial toxicity following surgical treatment for breast cancer: a cross-sectional pilot study. Ann Surg Oncol. 2021;28:2451–2462.
Sidey-Gibbons C, Asaad M, Pfob A, et al. Machine learning algorithms to predict financial toxicity associated with breast cancer treatment. J Clin Oncol. 2020;38(suppl 15):2047.
Tucker-Seeley RD, Yabroff KR. Minimizing the “financial toxicity” associated with cancer care: advancing the research agenda. JNCI. 2016;108:djv410.
Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973–1985.
Anderson MD Cancer center. randomized phase III trial of local consolidation therapy (LCT) after nivolumab and ipilimumab for immunotherapy-naive patients with metastatic non-small cell lung cancer (LONESTAR). PI: John Haymach, Open Label. Est Completion Date 12/31/2022 NCT03391869.
Hazell SZ, Fu W, Hu C, et al. Financial toxicity in lung cancer: an assessment of magnitude, perception, and impact on quality of life. Ann Oncol. 2020;31:96–102.
Friedes C, Hazell SZ, Fu W, et al. Longitudinal trends of financial toxicity in patients with lung cancer: a prospective cohort study. JCO Oncol Pract. 2021;17:OP2000721–e1109.
de Souza JA, Yap BJ, Wroblewski K, et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the Comprehensive Score for financial Toxicity (COST). Cancer. 2017;123:476–484.
Greenup RA, Rushing C, Fish L, et al. Financial costs and burden related to decisions for breast cancer surgery. J Oncol Pract. 2019;15:e666–e676.
Huntington SFD, Weiss BMMD, Vogl DTMD, et al. Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Haematol. 2015;2:e408–e416.
Bullock AJ, Hofstatter EW, Yushak M, et al. Understanding patients’ attitudes toward communication about the cost of cancer care. J Clin Oncol. 2011;29(suppl 15):6065.
Jagsi R, Ward KC, Abrahamse PH, et al. Unmet need for clinician engagement regarding financial toxicity after diagnosis of breast cancer. Cancer. 2018;124:3668–3676.
AJCC. Cancer Staging Manual, 8th edn. Springer International Publishing; 2018.
De Souza JA, Wroblewski K, Proussaloglou E, et al. Validation of a financial toxicity (FT) grading system. J Clin Oncol. 2017;35(suppl 15):6615.
Ver Hoeve ES, Ali-Akbarian L, Price SN, et al. Patient-reported financial toxicity, quality of life, and health behaviors in insured US cancer survivors. Support Care Cancer. 2020;29:349–358.
Zafar SY, McNeil RB, Thomas CM, et al. Population-based assessment of cancer survivors’ financial burden and quality of life: a prospective cohort study. J Oncol Pract. 2015;11:145–150.
Paranjpe R, John G, Trivedi M, et al. Identifying adherence barriers to oral endocrine therapy among breast cancer survivors. Breast Cancer Res Treat. 2018;174:297–305.
Tran G, Zafar SY. Financial toxicity and implications for cancer care in the era of molecular and immune therapies. Ann Transl Med. 2018;6:166.
Ürek D, Uğurluoğlu Ö. Predictors of financial toxicity and its associations with health-related quality of life and treatment non-adherence in Turkish cancer patients. Support Care Cancer. 2021;30:865–874.
Yabroff KR, Dowling EC, Guy JGP, et al. Financial hardship associated with cancer in the United States: findings from a population-based sample of adult cancer survivors. J Clin Oncol. 2016;34:259–267.
Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: a pilot study assessing out‐of‐pocket expenses and the insured cancer patient’s experience. Oncologist. 2013;18:381–390.
Corrigan KL, Fu S, Chen Y-S, et al. Financial toxicity impact on younger versus older adults with cancer in the setting of care delivery. Cancer. 2022;128:2455–2462.
Benavent KA, Chruscielski CM, Janssen SJ, et al. Patient perception and preferences for virtual telemedicine visits for hand and upper extremity surgery. Telemed J Ehealth. 2022;28:59–516.
Harting MT, Wheeler A, Ponsky T, et al. Telemedicine in pediatric surgery. J Pediatr Surg. 2019;54:587–594.
Healy P, McCrone L, Tully R, et al. Virtual outpatient clinic as an alternative to an actual clinic visit after surgical discharge: a randomised controlled trial. BMJ Qual Saf. 2019;28:24–31.
Uppal A, Kothari AN, Scally CP, et al. Adoption of telemedicine for postoperative follow-up after inpatient cancer-related surgery. JCO Oncol Pract. 2022;18:e1091–e1099.
Gribkova Y, Davis CH, Greenbaum AA, et al. Effect of the COVID‐19 pandemic on surgical oncology practice—results of an SSO survey. J Surg Oncol. 2022;125:1191–1199.
Sonagli M, Cagnacci Neto R, Leite FPM, et al. The use of telemedicine to maintain breast cancer follow‐up and surveillance during the COVID‐19 pandemic. J Surg Oncol. 2021;123:371–374.
Chi M. The hidden cost of cancer: helping clients cope with financial toxicity. Clin Soc Work J. 2017;47:249–257.
Zabora JR Christ G, Messner C, Behar L. Distress screening guidelines for oncology social workers. Handbook of oncology social work: Psychosocial care for people with cancer. New York, NY, US: Oxford University Press; 2015:115–119.
Ehlers M, Bjurlin M, Gore J, et al. A national cross-sectional survey of financial toxicity among bladder cancer patients. Urol Oncol. 2021;39:76.e1–e7.
Neilson T, Huynh V, Macdonald A, et al. Financial toxicity of breast cancer care: the patient perspective through surveys and interviews. J Surg Res. 2023;281:122–129.